{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse-Remitting+Multiple+Sclerosis&page=3",
    "query": {
      "condition": "Relapse-Remitting Multiple Sclerosis",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 282,
    "total_pages": 29,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse-Remitting+Multiple+Sclerosis&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Relapse-Remitting+Multiple+Sclerosis&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-04T07:43:16.326Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06526000",
      "title": "Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapsing Multiple Sclerosis",
        "Clinically Isolated Syndrome",
        "Relapsing-remitting Multiple Sclerosis",
        "Secondary Progressive Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 326,
      "start_date": "2022-10-11",
      "completion_date": "2024-02-28",
      "has_results": false,
      "last_update_posted_date": "2024-07-29",
      "last_synced_at": "2026-10-04T07:43:16.326Z",
      "location_count": 1,
      "location_summary": "East Hanover, New Jersey",
      "locations": [
        {
          "city": "East Hanover",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06526000"
    },
    {
      "nct_id": "NCT05964829",
      "title": "Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Multiple Sclerosis, Relapsing-Remitting",
        "Multiple Sclerosis, Chronic Progressive"
      ],
      "interventions": [
        {
          "name": "Cionic Neural Sleeve NS-100",
          "type": "DEVICE"
        },
        {
          "name": "Walking Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "BEHAVIORAL"
      ],
      "sponsor": "Cionic, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "22 Years to 75 Years"
      },
      "enrollment_count": 14,
      "start_date": "2023-09-04",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2025-09-24",
      "last_synced_at": "2026-10-04T07:43:16.326Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05964829"
    },
    {
      "nct_id": "NCT02019550",
      "title": "Rebif® Rebidose® Versus Rebiject II® Ease-of-Use",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing-Remitting"
      ],
      "interventions": [
        {
          "name": "Rebif Rebidose",
          "type": "DEVICE"
        },
        {
          "name": "Rebiject II",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "EMD Serono",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 97,
      "start_date": "2014-03",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-10-04T07:43:16.326Z",
      "location_count": 21,
      "location_summary": "Cullman, Alabama • Tuscon, Arizona • Newport Beach, California + 18 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Tuscon",
          "state": "Arizona"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Dover",
          "state": "Delaware"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02019550"
    },
    {
      "nct_id": "NCT05116540",
      "title": "Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "HB-adMSCs",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Hope Biosciences Research Foundation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 24,
      "start_date": "2021-11-24",
      "completion_date": "2024-06-04",
      "has_results": true,
      "last_update_posted_date": "2025-09-26",
      "last_synced_at": "2026-10-04T07:43:16.326Z",
      "location_count": 1,
      "location_summary": "Sugar Land, Texas",
      "locations": [
        {
          "city": "Sugar Land",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05116540"
    },
    {
      "nct_id": "NCT01396343",
      "title": "Environmental and Genetic Risk Factors for Pediatric Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pediatric Multiple Sclerosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "3 Years to 21 Years"
      },
      "enrollment_count": 1276,
      "start_date": "2011-10",
      "completion_date": "2018-04",
      "has_results": false,
      "last_update_posted_date": "2018-10-18",
      "last_synced_at": "2026-10-04T07:43:16.326Z",
      "location_count": 17,
      "location_summary": "Birmingham, Alabama • San Bernardino, California • San Francisco, California + 13 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Bernardino",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01396343"
    },
    {
      "nct_id": "NCT05705986",
      "title": "Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS)",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Relapse Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Blood Draw",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 40,
      "start_date": "2021-02-26",
      "completion_date": "2024-05",
      "has_results": false,
      "last_update_posted_date": "2023-01-31",
      "last_synced_at": "2026-10-04T07:43:16.326Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05705986"
    },
    {
      "nct_id": "NCT00835770",
      "title": "BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Relapsing-Remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "dimethyl fumarate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biogen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "58 Years",
        "sex": "ALL",
        "summary": "19 Years to 58 Years"
      },
      "enrollment_count": 1736,
      "start_date": "2009-02-03",
      "completion_date": "2019-11-08",
      "has_results": true,
      "last_update_posted_date": "2020-12-31",
      "last_synced_at": "2026-10-04T07:43:16.326Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Mesa, Arizona + 44 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00835770"
    },
    {
      "nct_id": "NCT07667322",
      "title": "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab Co-formulated With rHuPH20",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 75,
      "start_date": "2024-12-17",
      "completion_date": "2028-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-04T07:43:16.326Z",
      "location_count": 6,
      "location_summary": "Carlsbad, California • Maitland, Florida • Tampa, Florida + 3 more",
      "locations": [
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Maitland",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07667322"
    },
    {
      "nct_id": "NCT05755061",
      "title": "WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Relapsing-remitting Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "GEMS Plus",
          "type": "BEHAVIORAL"
        },
        {
          "name": "GEMS",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Kessler Foundation",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 31,
      "start_date": "2023-02-01",
      "completion_date": "2027-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-04T07:43:16.326Z",
      "location_count": 1,
      "location_summary": "West Orange, New Jersey",
      "locations": [
        {
          "city": "West Orange",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05755061"
    },
    {
      "nct_id": "NCT06629428",
      "title": "Effects of Ublituximab on Motor Functions in Multiple Sclerosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis (MS) - Relapsing-remitting"
      ],
      "interventions": [
        {
          "name": "Ublituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgia State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 25,
      "start_date": "2025-11-13",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-10-04T07:43:16.326Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06629428"
    }
  ]
}